explore -WSS

explore

author：comprehensive 2025-09-06 04:13:29 - browse：4857

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： New Medicare drug pricing powers could soon be upended in court

focus

entertainment

WSS

Are embryos people? Reproductive medicine's future depends on the answer

New menopause drug shows promise in relief for hot flashes

Pfizer is about to make a big push in cancer. Will investors listen?

Three issues to watch in global health in 2024

5 ways to address the shortage of health care workers

Elisabeth Bik tackles the widespread issue of research misconduct

focus

explore

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Childhood vaccination ad campaign launches in the U.K.

Apple is now the first public company to be valued at $3 trillion

Elisabeth Bik tackles the widespread issue of research misconduct

At least 13 dead in Texas as scorching temps continue

How I ended up pumping milk in a bathroom stall at JPM 2024

How one medical school became remarkably diverse

Doulas covered by Medicaid under New York's new plan

At least 13 dead in Texas as scorching temps continue

Fauci’s Covid grilling leads GOP to weigh foreign research rules

hotspot

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Doctor of U.S. President Joe Biden says he is fit for duty

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

New England Journal of Medicine addresses racist history, slavery

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Laying a path for careers in science

knowledge

focus

entertainment

explore